Reducing immunogenicity of therapeutic antibodies has been an ongoing initiative of the biopharmaceutical industry since the inception of the first human therapeutic use of mouse-derived antibodies in the 1980s. A variety of technical approaches have been developed over the years to "humanize" or develop so-called "fully human" antibodies. These engineering approaches do not however enable production of naturally occurring antibodies. Due to the difficulty of identifying and cloning naturally occurring antibodies, to date, no naturally occurring, or True Human™ antibodies, have been developed as human monoclonal antibody therapeutic products.
XBiotech is the leader in commercialization of True Human™ antibody therapy.